Integrating HIV prevention and treatment: From slogans to impact

Joshua A. Salomon, Daniel R. Hogan, John Stover, Karen A. Stanecki, Neff Walker, Peter D. Ghys, Bernhard Schwartländer

Research output: Contribution to journalArticle

Abstract

Background: Through major efforts to reduce costs and expand access to antiretroviral therapy worldwide, widespread delivery of effective treatment to people living with HIV/AIDS is now conceivable even in severely resource-constrained settings. However, the potential epidemiologic impact of treatment in the context of a broader strategy for HIV/AIDS control has not yet been examined. In this paper, we quantify the opportunities and potential risks of large-scale treatment roll-out. Methods and Findings: We used an epidemiologic model of HIV/AIDS, calibrated to sub-Saharan Africa, to investigate a range of possible positive and negative health outcomes under alternative scenarios that reflect varying implementation of prevention and treatment. In baseline projections, reflecting "business as usual," the numbers of new infections and AIDS deaths are expected to continue rising. In two scenarios representing treatment-centered strategies, with different assumptions about the impact of treatment on transmissibility and behavior, the change in the total number of new infections through 2020 ranges from a 10% increase to a 6% reduction, while the number of AIDS deaths through 2020 declines by 9% to 13%. A prevention-centered strategy provides greater reductions in incidence (36%) and mortality reductions similar to those of the treatment-centered scenarios by 2020, but more modest mortality benefits over the next 5 to 10 years. If treatment enhances prevention in a combined response, the expected benefits are substantial - 29 million averted infections (55%) and 10 million averted deaths (27%) through the year 2020. However, if a narrow focus on treatment scale-up leads to reduced effectiveness of prevention efforts, the benefits of a combined response are considerably smaller-9 million averted infections (17%) and 6 million averted deaths (16%). Combining treatment with effective prevention efforts could reduce the resource needs for treatment dramatically in the long term. In the various scenarios the numbers of people being treated in 2020 ranges from 9.2 million in a treatment-only scenario with mixed effects, to 4.2 million in a combined response scenario with positive treatment-prevention synergies. Conclusions: These analyses demonstrate the importance of integrating expanded care activities with prevention activities if there are to be long-term reductions in the number of new HIV infections and significant declines in AIDS mortality. Treatment can enable more effective prevention, and prevention makes treatment affordable. Sustained progress in the global fight against HIV/AIDS will be attained only through a comprehensive response.

Original languageEnglish (US)
Pages (from-to)50-56
Number of pages7
JournalPLoS Medicine
Volume2
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

Acquired Immunodeficiency Syndrome
HIV
Infection
Mortality
Africa South of the Sahara
HIV Infections
Costs and Cost Analysis
Incidence
Health

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Salomon, J. A., Hogan, D. R., Stover, J., Stanecki, K. A., Walker, N., Ghys, P. D., & Schwartländer, B. (2005). Integrating HIV prevention and treatment: From slogans to impact. PLoS Medicine, 2, 50-56. https://doi.org/10.1371/journal.pmed.0020016

Integrating HIV prevention and treatment : From slogans to impact. / Salomon, Joshua A.; Hogan, Daniel R.; Stover, John; Stanecki, Karen A.; Walker, Neff; Ghys, Peter D.; Schwartländer, Bernhard.

In: PLoS Medicine, Vol. 2, 2005, p. 50-56.

Research output: Contribution to journalArticle

Salomon, JA, Hogan, DR, Stover, J, Stanecki, KA, Walker, N, Ghys, PD & Schwartländer, B 2005, 'Integrating HIV prevention and treatment: From slogans to impact', PLoS Medicine, vol. 2, pp. 50-56. https://doi.org/10.1371/journal.pmed.0020016
Salomon, Joshua A. ; Hogan, Daniel R. ; Stover, John ; Stanecki, Karen A. ; Walker, Neff ; Ghys, Peter D. ; Schwartländer, Bernhard. / Integrating HIV prevention and treatment : From slogans to impact. In: PLoS Medicine. 2005 ; Vol. 2. pp. 50-56.
@article{5387e292fb694cda88fa0aa32c4587cf,
title = "Integrating HIV prevention and treatment: From slogans to impact",
abstract = "Background: Through major efforts to reduce costs and expand access to antiretroviral therapy worldwide, widespread delivery of effective treatment to people living with HIV/AIDS is now conceivable even in severely resource-constrained settings. However, the potential epidemiologic impact of treatment in the context of a broader strategy for HIV/AIDS control has not yet been examined. In this paper, we quantify the opportunities and potential risks of large-scale treatment roll-out. Methods and Findings: We used an epidemiologic model of HIV/AIDS, calibrated to sub-Saharan Africa, to investigate a range of possible positive and negative health outcomes under alternative scenarios that reflect varying implementation of prevention and treatment. In baseline projections, reflecting {"}business as usual,{"} the numbers of new infections and AIDS deaths are expected to continue rising. In two scenarios representing treatment-centered strategies, with different assumptions about the impact of treatment on transmissibility and behavior, the change in the total number of new infections through 2020 ranges from a 10{\%} increase to a 6{\%} reduction, while the number of AIDS deaths through 2020 declines by 9{\%} to 13{\%}. A prevention-centered strategy provides greater reductions in incidence (36{\%}) and mortality reductions similar to those of the treatment-centered scenarios by 2020, but more modest mortality benefits over the next 5 to 10 years. If treatment enhances prevention in a combined response, the expected benefits are substantial - 29 million averted infections (55{\%}) and 10 million averted deaths (27{\%}) through the year 2020. However, if a narrow focus on treatment scale-up leads to reduced effectiveness of prevention efforts, the benefits of a combined response are considerably smaller-9 million averted infections (17{\%}) and 6 million averted deaths (16{\%}). Combining treatment with effective prevention efforts could reduce the resource needs for treatment dramatically in the long term. In the various scenarios the numbers of people being treated in 2020 ranges from 9.2 million in a treatment-only scenario with mixed effects, to 4.2 million in a combined response scenario with positive treatment-prevention synergies. Conclusions: These analyses demonstrate the importance of integrating expanded care activities with prevention activities if there are to be long-term reductions in the number of new HIV infections and significant declines in AIDS mortality. Treatment can enable more effective prevention, and prevention makes treatment affordable. Sustained progress in the global fight against HIV/AIDS will be attained only through a comprehensive response.",
author = "Salomon, {Joshua A.} and Hogan, {Daniel R.} and John Stover and Stanecki, {Karen A.} and Neff Walker and Ghys, {Peter D.} and Bernhard Schwartl{\"a}nder",
year = "2005",
doi = "10.1371/journal.pmed.0020016",
language = "English (US)",
volume = "2",
pages = "50--56",
journal = "Nature Clinical Practice Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Integrating HIV prevention and treatment

T2 - From slogans to impact

AU - Salomon, Joshua A.

AU - Hogan, Daniel R.

AU - Stover, John

AU - Stanecki, Karen A.

AU - Walker, Neff

AU - Ghys, Peter D.

AU - Schwartländer, Bernhard

PY - 2005

Y1 - 2005

N2 - Background: Through major efforts to reduce costs and expand access to antiretroviral therapy worldwide, widespread delivery of effective treatment to people living with HIV/AIDS is now conceivable even in severely resource-constrained settings. However, the potential epidemiologic impact of treatment in the context of a broader strategy for HIV/AIDS control has not yet been examined. In this paper, we quantify the opportunities and potential risks of large-scale treatment roll-out. Methods and Findings: We used an epidemiologic model of HIV/AIDS, calibrated to sub-Saharan Africa, to investigate a range of possible positive and negative health outcomes under alternative scenarios that reflect varying implementation of prevention and treatment. In baseline projections, reflecting "business as usual," the numbers of new infections and AIDS deaths are expected to continue rising. In two scenarios representing treatment-centered strategies, with different assumptions about the impact of treatment on transmissibility and behavior, the change in the total number of new infections through 2020 ranges from a 10% increase to a 6% reduction, while the number of AIDS deaths through 2020 declines by 9% to 13%. A prevention-centered strategy provides greater reductions in incidence (36%) and mortality reductions similar to those of the treatment-centered scenarios by 2020, but more modest mortality benefits over the next 5 to 10 years. If treatment enhances prevention in a combined response, the expected benefits are substantial - 29 million averted infections (55%) and 10 million averted deaths (27%) through the year 2020. However, if a narrow focus on treatment scale-up leads to reduced effectiveness of prevention efforts, the benefits of a combined response are considerably smaller-9 million averted infections (17%) and 6 million averted deaths (16%). Combining treatment with effective prevention efforts could reduce the resource needs for treatment dramatically in the long term. In the various scenarios the numbers of people being treated in 2020 ranges from 9.2 million in a treatment-only scenario with mixed effects, to 4.2 million in a combined response scenario with positive treatment-prevention synergies. Conclusions: These analyses demonstrate the importance of integrating expanded care activities with prevention activities if there are to be long-term reductions in the number of new HIV infections and significant declines in AIDS mortality. Treatment can enable more effective prevention, and prevention makes treatment affordable. Sustained progress in the global fight against HIV/AIDS will be attained only through a comprehensive response.

AB - Background: Through major efforts to reduce costs and expand access to antiretroviral therapy worldwide, widespread delivery of effective treatment to people living with HIV/AIDS is now conceivable even in severely resource-constrained settings. However, the potential epidemiologic impact of treatment in the context of a broader strategy for HIV/AIDS control has not yet been examined. In this paper, we quantify the opportunities and potential risks of large-scale treatment roll-out. Methods and Findings: We used an epidemiologic model of HIV/AIDS, calibrated to sub-Saharan Africa, to investigate a range of possible positive and negative health outcomes under alternative scenarios that reflect varying implementation of prevention and treatment. In baseline projections, reflecting "business as usual," the numbers of new infections and AIDS deaths are expected to continue rising. In two scenarios representing treatment-centered strategies, with different assumptions about the impact of treatment on transmissibility and behavior, the change in the total number of new infections through 2020 ranges from a 10% increase to a 6% reduction, while the number of AIDS deaths through 2020 declines by 9% to 13%. A prevention-centered strategy provides greater reductions in incidence (36%) and mortality reductions similar to those of the treatment-centered scenarios by 2020, but more modest mortality benefits over the next 5 to 10 years. If treatment enhances prevention in a combined response, the expected benefits are substantial - 29 million averted infections (55%) and 10 million averted deaths (27%) through the year 2020. However, if a narrow focus on treatment scale-up leads to reduced effectiveness of prevention efforts, the benefits of a combined response are considerably smaller-9 million averted infections (17%) and 6 million averted deaths (16%). Combining treatment with effective prevention efforts could reduce the resource needs for treatment dramatically in the long term. In the various scenarios the numbers of people being treated in 2020 ranges from 9.2 million in a treatment-only scenario with mixed effects, to 4.2 million in a combined response scenario with positive treatment-prevention synergies. Conclusions: These analyses demonstrate the importance of integrating expanded care activities with prevention activities if there are to be long-term reductions in the number of new HIV infections and significant declines in AIDS mortality. Treatment can enable more effective prevention, and prevention makes treatment affordable. Sustained progress in the global fight against HIV/AIDS will be attained only through a comprehensive response.

UR - http://www.scopus.com/inward/record.url?scp=13844301323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844301323&partnerID=8YFLogxK

U2 - 10.1371/journal.pmed.0020016

DO - 10.1371/journal.pmed.0020016

M3 - Article

C2 - 15647780

AN - SCOPUS:13844301323

VL - 2

SP - 50

EP - 56

JO - Nature Clinical Practice Oncology

JF - Nature Clinical Practice Oncology

SN - 1759-4774

ER -